(Q34519666)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830755%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830755%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

1 reference

D Braida

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830755%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

M Sala

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830755%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 January 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830755%20AND%20SRC:MED&resulttype=core&format=json

CNS Neuroscience & Therapeutics

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830755%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830755%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830755%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

369-386

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830755%20AND%20SRC:MED&resulttype=core&format=json

Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.

6 December 2019

cites work

1 reference

12 December 2020

Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.

1 reference

12 December 2020

Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication.

1 reference

12 December 2020

Effects of cholinergic drugs on neocortical EEG and flash-visual evoked potentials in the mouse.

1 reference

12 December 2020

Treatment of Alzheimer's disease

1 reference

12 December 2020

A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease.

1 reference

12 December 2020

Protection of mice against soman by pretreatment with eptastigmine and physostigmine

1 reference

12 December 2020

Excitatory and inhibitory effects of second-generation cholinesterase inhibitors on rat gastrointestinal transit

1 reference

12 December 2020

Effects of cholinesterase inhibitors on a two-component chained schedule performance in rats.

1 reference

12 December 2020

Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats.

1 reference

12 December 2020

Eptastigmine improves eight-arm radial maze performance in aged rats

1 reference

12 December 2020

Eptastigmine restores the aged rat's normal cortical spectral power pattern

1 reference

12 December 2020

Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain

1 reference

12 December 2020

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

1 reference

12 December 2020

The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze

1 reference

12 December 2020

Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL)

1 reference

12 December 2020

Preferential inhibition of acetylcholinesterase molecular forms in rat brain

1 reference

12 December 2020

Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates

1 reference

12 December 2020

Determination of heptylphysostigmine in plasma by high-performance liquid chromatography with electrochemical detection

1 reference

12 December 2020

Pharmacokinetics of heptastigmine in rats

1 reference

12 December 2020

Heptyl-physostigmine enhances basal forebrain control of cortical cerebral blood flow

1 reference

12 December 2020

The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents

1 reference

12 December 2020

Kinetics of cholinesterase inhibition by eptastigmine in man.

1 reference

12 December 2020

The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat

1 reference

12 December 2020

A long-lasting cholinesterase inhibitor affecting neural and behavioral processes.

1 reference

12 December 2020

Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia.

1 reference

12 December 2020

Cholinesterase inhibitors increase secretion of APPs in rat brain cortex.

1 reference

12 December 2020

Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers

1 reference

12 December 2020

A patient-side technique for real-time measurement of acetylcholinesterase activity during monitoring of eptastigmine treatment.

1 reference

12 December 2020

Coadministration of cholinesterase inhibitors and idazoxan: effects of neurotransmitters in rat cortex in vivo

1 reference

12 December 2020

The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus basalis

1 reference

12 December 2020

A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase

1 reference

12 December 2020

Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo.

1 reference

12 December 2020

The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory.

1 reference

12 December 2020

Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain

1 reference

12 December 2020

Effect of acute and short-term administration of cholinomimetic drugs on corticosterone secretion in the rat

1 reference

12 December 2020

Approaches to cholinergic therapy in Alzheimer's disease

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects

1 reference

12 December 2020

Prolonged effects of cholinesterase inhibition with eptastigmine on the cerebral blood flow-metabolism ratio of normal rats

1 reference

12 December 2020

Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs

1 reference

12 December 2020

Determination of heptylphysostigmine in plasma by high-performance liquid chromatography with electrochemical detection

1 reference

12 December 2020

Rapid potentiometric determination of cholinesterases in plasma and red cells: application to eptastigmine monitoring

1 reference

12 December 2020

The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study".

1 reference

12 December 2020

Cholinergic modulation of a decrement in social investigation following repeated contacts between mice

1 reference

12 December 2020

Alpha 2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat.

1 reference

12 December 2020

An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors.

1 reference

12 December 2020

Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.

1 reference

12 December 2020

Effects of MF-268, a new cholinesterase inhibitor, on acetylcholine and biogenic amines in rat cortex

1 reference

12 December 2020

Eptastigmine-phosphotriesterase combination in DFP intoxication.

1 reference

12 December 2020

Phosphotriesterase, pralidoxime-2-chloride (2-PAM) and eptastigmine treatments and their combinations in DFP intoxication.

1 reference

12 December 2020

Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex.

1 reference

12 December 2020

From molecular structure to Alzheimer therapy

1 reference

12 December 2020

Effect of the subchronic treatment with the acetylcholinesterase inhibitor heptastigmine on central cholinergic transmission and memory impairment in aged rats.

1 reference

12 December 2020

Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications

1 reference

12 December 2020

Effect of food on the absorption of eptastigmine

1 reference

12 December 2020

Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers

1 reference

12 December 2020

Cholinergic foundations of Alzheimer's disease therapy

1 reference

12 December 2020

A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease.

1 reference

12 December 2020

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

1 reference

12 December 2020

10.1111/J.1527-3458.2001.TB00205.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830755%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11830755%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference